News
Displaying 191–200 of 541
-
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Research NewsInterim results for pediatric patients with CNGB3 mutations were encouraging
-
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
Research NewsThis new treatment can reduce the frequency of injections into the eye
-
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
Research NewsThe Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
Foundation News
Commitment to expand translational research acceleration program and fund career development award.
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
-
Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer
Foundation NewsNoteworthy Foundation executive increases role within organization.
-
Research News
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
Research News
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
In the PressInvestment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
In the Press
Series B new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, and the RD Fund (the venture arm of Foundation Fighting Blindness).
.png)
.png)
